Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-06-05
2007-06-05
Siew, Jeffrey (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S190100, C424S239100, C530S350000
Reexamination Certificate
active
10463957
ABSTRACT:
An active or passive vaccine utilizing purified non-toxic mutant TcdB toxins fromClostridium difficilefor humans and animals against infections caused byC. difficileand/orC. sordellii.Persons most potentially affected byC. difficileinfections include hospitalized patients, infants, and elderly persons. The TcdB toxin mutant of the vaccine preferably lacks the toxicity of a nativeC. difficileTcdB toxin. A serum comprising antibodies raised to the TcdB toxin mutant is also available for treating humans or animals againstC. difficileinfections. The serum may be used in a method for conferring passive immunity againstC. difficile.Antibodies to the TcdB toxin mutant may be used in diagnostic tests or in treatments to clear TcdB toxin from bodily fluids. The mutant TcdB toxin may be produced by recombinant methods using cDNA encoding the toxin, the cDNA contained for example in a plasmid or host cell.
REFERENCES:
patent: PCT/US 03/19230 (2004-09-01), None
Spyres et al. ,Infection and Immunity vol. 71, No. 6, pp. 3294-3301, 2003.
Barroso et al. ,Microbial Pathogenesis vol. 16, pp. 297-303, 1994.
Barroso et al. ,Nucleic Acid Research vol. 18, No. 13, p. 4004, 1990.
Sequence alignment S10317.
Busch, C., Hofmann, F., Gerhard, R., and Aktories; K. (2000) “Involvement of a conserved tryptophan residue in the UDP-glucose binding of large clostridial cytotoxin glycosyltransferases”J Biol Chem275, 13228-13234.
Ciesla, W.P., Jr., and Bobak, D.A. (1998) “Clostridium difficiletoxins A and B are cation-dependent UDP-glucose hydrolases with differing catalytic activities”J Biol Chem273, 16021-16026.
Hofmann, F., Busch, C., and Aktories, K. (1998) “Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition”Infect Immun66, 1076-1081.
Qa'Dan, M., Spyres, L.M., and Ballard, J.D. (2000) “pH-induced conformational changes inClostridium difficiletoxin B”Infect Immun68, 2470-2474.
Qa'Dan, M., Spyres, L.M., and Ballard, J.D. (2001) “pH-Enhanced Cytopathic Effects ofClostridium sordelliiLethal Toxin”Infect Immun69, 5487-5493.
Spyres, L.M., Qa'Dan, M., Meader, A., Tomasek, J.J., Howard, E.W., and Ballard, J.D. (2001) “Cytosolic delivery and characterization of the TcdB glucosylating domain by using a heterologous protein fusion”Infect Immun69, 599-601.
Starnbach, M.N., and Bevan, M.J. (1994) “Cells infected with Yersinia present an epitope to class I MHC-restricted CTL”Journal of Immunology153, 1603-1612.
Whilhite, D.C., and Blanke, S.R. (1998) Soluble Expression and One-Step Purification of RecombinantBacillus anthracisProtective Antigen Protein and Peptide Letters 5, 273-278.
Barroso et al., “Mutagenesis of theClostridium difficiletoxin B gene and effect on cytotoxic activity”,Microbial Pathogenesis, Academic Press Limited, New York, NY, US, vol. 16, No. 4, 1994, pp. 297-303, XP002100213.
Spyres et al., “Deletion Analysis of theClostridium difficileToxin B Glycosylation Domain”, Abstracts of the General Meeting of the American Society for Microbiology, vol. 101, May 20, 2001, p. 94, XP002292782.
Spyres et al., “Mutational Analysis of the Enzymatic Domain ofClostridium difficileToxin B Reveals Novel Inhibitors of the Wild-Type Toxin”,Infection and Immunity, vol. 71, No. 6, Jun. 2003, pp. 3294-3301, XP002292785.
Ballard Jimmy D.
Spyres Lea M.
Dunlap Codding & Rogers P.C.
Siew Jeffrey
The Board of Regents of the University of Oklahoma
LandOfFree
Mutants of Clostridium difficile toxin B and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutants of Clostridium difficile toxin B and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutants of Clostridium difficile toxin B and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845770